Search Browse Earnings

Sagimet Biosciences Inc. — SlamSEC

Sagimet Biosciences Inc.

Nasdaq:SGMT

Pharmaceutical Preparations·SAN MATEO, CA

Overview All Filings Sum Fin Credit Insiders Governance

Overview All Filings Sum Fin Credit Insiders Governance

Summary Financials

Revenue

$2.0M

+0.0% YoY

FY 2024

Adj. EBITDA

—

Net Income

-$45.6M

-2278.3% margin

FY 2025

EPS (Diluted)

-$1.45

FY 2025

Stock Price

$5.21

-2.4%

2026-03-13

52W Range

$1.73 – $11.41

P/E Ratio

-3.6x

Market Cap

$159.8M

Cash

$75.8M

FY 2025

Total Debt

—

Net Cash

$75.8M

FY 2024

Enterprise Value

$84.0M

Debt / EBITDA

—

EV / EBITDA

—

Employees

—

CEO

Happel David

CFO

Chauche Thierry